An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension

Bibliography

• LEONARD R: Statistics on Vision Impairment: A Resource Manual Oh ednI Arlene R (Ed.), Gordon Research Institute of Lighthouse International, New York, USA (2002).
   Google Scholar
• EUROPEAN GLAUCOMA SOCIETY:Terminology and Guidelines for Glaucoma(2'd edn). European Glaucoma Society, Savona, Italy (2003).
   Google Scholar
• ••Important guidelines for the managementof glaucoma.
   Google Scholar
• THE AGIS INVESTIGATORS: The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am. I Ophthalmol. (2000) 130:429–440.
   PubMed Web of Science ®Google Scholar
• •An important glaucoma study with great impact on treatment strategies.
   Google Scholar
• HOYNG PFJ, VAN BEEK LM:Pharmacological therapy for glaucoma.A review. Drugs (2000) 59:411–434.
   PubMedGoogle Scholar
• •A good review of medical treatments for glaucoma.
   Google Scholar
• ALM A, WIDENGARD I,KJELLGREN D et al: Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br. j Ophthalmol. (1995) 79:12–16.
   PubMed Web of Science ®Google Scholar
• ••A pivotal early clinical trial of concomitanttreatment with latanoprost and timolol.
   Google Scholar
• BUCCI MG, AND THE ITALIAN LATANOPROST STUDY GROUP: Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma.Glaucoma (1999) 8:24–30.
   PubMed Web of Science ®Google Scholar
• WEINREB RN: Compliance with medical treatment of glaucoma. Glaucoma (1992) 1:134–136.
   Google Scholar
• PATEL SC, SPAETH GL: Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. (1995) 26:233–236.
   PubMedGoogle Scholar
• AMERICAN ACADEMY OF OPHTHALMOLOGY: Preferred Practice Pattern. Primary Open-Angle Glaucoma Suspect. [online] Revised: September (2002).
   Google Scholar
• ••Important guidelines for the managementof ocular hypertension.
   Google Scholar
• MAUGER TF, CRAIG EL: Ocular pharmacokinetics. In: Mosby's Ocular Drug Handbook. Mosby-Year Book Inc., St Louis, MO, USA (1996):3–18.
   Google Scholar
• GOTO Y, NOBUHIRO I, MIYAKE K: Human lens epithelial cell damage and stimulation of their secretion of chemical mediators by benzalkonium chloride rather than latanoprost and timolol.Arch. Ophthalmol (2003) 121:835–839.
   PubMed Web of Science ®Google Scholar
• PERRY CM, MC GAVIN JK, CULY CR, IBBOTSON T: Latanoprost. An update of its use in glaucoma and ocular hypertension. Drugs Aging (2003) 20:597–630.
   PubMed Web of Science ®Google Scholar
• •A thorough review of latanoprost.
   Google Scholar
• BROOKS AMV, GILLIES WE: Ocular I3-blockers in glaucoma management. Clinical pharmacological aspects. Drugs Aging (1992) 2:208–221.
   PubMed Web of Science ®Google Scholar
• RULO AH, GREVE EL, HOYNG PFH: Additive effect of latanoprost, a prostaglandin Fac analogue, and timolol in patients with elevated intraocular pressure. Br. Ophthalmol (1994) 78:899–902.
   PubMed Web of Science ®Google Scholar
• BRON AM, DENIS P, NORDMANN JP, ROULAND JF, SELLEM E, JOHANSSON M: Additive I0P-reducing effect of latanoprost in patients insufficiently controlled on timolol. Acta Ophthalmol Scand. (2001) 79:289–293.
   PubMedGoogle Scholar
• HIGGINBOTHAM EJ,DIESTELHORST M, PFEIFFER N,ROULAND JF, ALM A: The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications. Surv. Ophthalmol (2002) 47\(Supp1.1):S133–S140.
   Google Scholar
• •A good overview of studies using latanoprost in combination with other antiglaucoma medications.
   Google Scholar
• Pfizer, Inc.: Xalatan® (Latanoprost ) package insert. Pfizer, Inc., New York, NY, USA (2003).
   Google Scholar
• MCEVOY GK (Ed.): Latanoprost. In: American Hospital Formulary Service Drug Information° 2000. American Society of Health-System Pharmacists. Bethesda, MD, USA (2000):2596–2600.
   Google Scholar
• Merck & Co.: Timoptic'" (Timolol ) package insert. Merck & Co., Whitehouse Station, NJ, USA (2001).
   Google Scholar
• MCEVOY GK (Ed.): Timolol. In: American Hospital Formulary Service Drug Information° 2000. American Society of Health-System Pharmacists, Bethesda, MD, USA (2000):2603–2606.
   Google Scholar
• STJERNSCHANTZ JW: From PGF2“ - isopropyl ester to latanoprost: a review of the development of Xalatan. The Proctor Lecture. Invest. Ophthalmol Vis. Sci. (2001) 42:1134–1145.
   PubMed Web of Science ®Google Scholar
• BASU S, SJOQUIST BJ, RESUL B, STJERNSCHANTZ JW: Corneal permeability to and ocular metabolism of phenyl substituted prostaglandin esters in vitro. Prostaglandins Leukot. Essent. Fatty Acids (1994) 50:161–168.
   PubMed Web of Science ®Google Scholar
• TORTS CB, CAMRAS CB,YABLONSKI ME: Effects of PhXA41, a new prostaglandin F2“ analog, on aqueous humor dynamics in human eyes. Ophthalmology (1993) 100:1297–1304.
   PubMed Web of Science ®Google Scholar
• ZIAI N, DOLAN JW, KACERE RD, BRUBAKER RF: The effects on aqueous dynamics of PhXA41, a new prostaglandin F2“ analogue, after topical application in normal and ocular hypertensive human eyes. Arch. Ophthalmol (1993) 111:1351–1358.
   PubMed Web of Science ®Google Scholar
• TORTS CB, CAMRAS CB, YABLONSKI ME, BRUBAKER RF: Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function.Surv. Ophthalmol (1997)41\(Suppl. 2):569–575.
   Google Scholar
• GABELT BT, KAUFMAN PL: The effect of prostaglandin F2“ on trabecular outflowfacility in cynomolgus monkeys. Exp. Eye Res. (1990) 51:87–91.
   PubMed Web of Science ®Google Scholar
• OCKLIND A, LAKE S, WENTZEL P, NISTER M, STJERNSCHANTZ J: Localization of the prostaglandin F2“ receptor messenger RNA and protein in the cynomolgus monkey eye.Invest. Ophthalmol Vis. Sci. (1996) 37:716–726.
   PubMed Web of Science ®Google Scholar
• ZHAN G-L, CAMRAS CB, OPERE C, TANG L, OHIA SE: Effect of prostaglandins on cyclic AMP production in cultured human ciliary muscle cells. J. Ocul. Pharmacol Ther. (1998) 14:45–55.
   PubMedGoogle Scholar
• SCHACHTSCHABEL U, LINDSEY JD,WEINREB RN: The mechanism of action of prostaglandins on uveoscleral outflow. Carr. Opin. Ophthalmol (2000) 11:112–115.
   PubMedGoogle Scholar
• LINDSEY JD, KASHIWAGI K, BOYLE D, KASHIWAGI F, FIRESTEIN GS, WEINREB RN: Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells.Carr. Eye Res. (1996) 15:869–875.
   PubMed Web of Science ®Google Scholar
• WEINREB RN, KASHIWAGI K, KASHIWAGI F, TSUKAHARA S, LINDSEY JD: Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest. Ophthalmol Vis. Sci. (1997) 38:2772–2780.
   PubMed Web of Science ®Google Scholar
• SAGARA T, GATON DD, LINDSEY JD,GABELT BT, KAUFMAN PL, WEINREB RN: Topical prostaglandin F2“ treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch. Ophthalmol (1999) 117:794–801.
   PubMed Web of Science ®Google Scholar
• POYER JF, MILLAR C, KAUFMAN PL: Prostaglandin F2“ effects on isolated rhesus monkey ciliary muscle. Invest. Ophthalmol Vis. Sci. (1995) 36:2461–2465.
   PubMed Web of Science ®Google Scholar
• YOUSUFZAI SYK, YE Z, ABDEL-LATIF AA: Prostaglandin F2“ and its analogs induce release of endogenous prostaglandins in iris and ciliary muscles isolated from cat and other mammalian species. Exp. Eye Res. (1996) 63:305–310.
   PubMedGoogle Scholar
• NICOLELA MT, BUCKLEY AR, WALMAN BE, DRANCE SM: A comparative study of the effects of timolol and latanoprost on blood flow velocity of the retrobulbar vessels. Am. .1. Ophthalmol (1996) 122:784–789.
   PubMed Web of Science ®Google Scholar
• SEONG GJ, LEE HK, HONG YJ: Effectsof 0.005% latanoprost on optic nerve head and peripapillary retinal blood flow. Ophthalmologica (1999) 213:355–359.
   PubMed Web of Science ®Google Scholar
• ISHII K, TOMIDOKORO A, NAGAHARA M et al.: Effects of topical latanoprost on optic nerve head circulation in rabbits, monkeys, and humans. Invest. Ophthalmol Vis. Sci. (2001) 42:2957–2963.
   PubMed Web of Science ®Google Scholar
• DRAGO F, VALZELLI S, EMMI I, MARINO A, SCALIA CC, MARINO V: Latanoprost exerts neuroprotective activity in vitro and in vivo. Exp. Eye Res. (2001) 72:479–486.
   PubMed Web of Science ®Google Scholar
• LARSSON L-I: The effect on diurnal intraocular pressure of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension. Acta Ophthalmol Scand. (2001) 79:125–128.
   PubMedGoogle Scholar
• LARSSON L-I: Intraocular pressure over 24 hours after single-dose administration of latanoprost 0.005% in healthy volunteers. A randomized, double-masked, placebo controlled, cross-over single center study. Acta Ophthalmol. Scand. (2001) 79:567–571.
   PubMedGoogle Scholar
• MISHIMA HK, KIUCHI Y, TAKAMATSU M, RÁCZ P, BITO LZ: Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow. Surv. Ophthalmol (1997) 41\(Suppl. 2):S139–S144.
   Google Scholar
• RÁCZ P, RUZSONYI MR, NAGY ZT, GAGYI Z, BITO LZ: Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol. Arch. Ophthalmol. (1996) 114:268–273.
   PubMed Web of Science ®Google Scholar
• LARSSON L-I, MISHIMA HK, TAKAMATSU M, ORZALESI N, ROSSETTI L: The effect of latanoprost on circadian intraocular pressure. Surv. Ophthalmol (2002) 47\(Supp1.1):S90–S96.
   Google Scholar
• HEDNER J, SVEDMYR N, LUNDE H, MANDAHL A: The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma. Surv. Ophthalmol (1997) 41\(Suppl. 2):S111–S115.
   Google Scholar
• KERSTETTER JR, BRUBAKER RE WILSON SE, KULLERSTRAND LJ: Prostaglandin Facl-isopropylester lowers intraocular pressure without decreasing aqueous humor flow. Am. I. Ophthalmol (1988) 105:30–34.
   PubMed Web of Science ®Google Scholar
• VILLUMSEN J, ALM A: Prostaglandin F2a-isopropylester eye drops: effects in normal human eyes. Br. J. Ophthalmol (1989) 73:419–426.
   PubMedGoogle Scholar
• COAKES RL, BRUBAKER RF: The mechanism of timolol in lowering intraocular pressure. In the normal eye. Arch. Ophthalmol (1978) 96:2045–2048.
   PubMed Web of Science ®Google Scholar
• YABLONSKI ME, ZIMMERMAN TJ, WALTMAN SR, BECKER B: A fluorophotometric study of the effect of topical timolol on aqueous humor dynamics. Exp. Eye Res. (1978) 27:135–142.
   PubMed Web of Science ®Google Scholar
• ZIMMERMAN TJ, HARBIN R, PETT M, KAUFMAN HE: Timolol and facility of outflow. Invest. Ophthalmol Vis. Sci. (1977) 16:623–624.
   PubMed Web of Science ®Google Scholar
• SONNTAG JR, BRINDLEY GO, SHIELDS MB: Effect of timolol therapy on outflow facility. Invest. Ophthalmol Vis. Sci. (1978) 17:293–296.
   PubMed Web of Science ®Google Scholar
• MC LAUGHLIN CW, PEART D, PURVES RD et al.: Timolol may inhibit aqueous humor secretion by cAMP-independent action on the ciliary epithelial cells. Am. Physiol Cell Physiol. (2001) 281:C865–C875.
   Google Scholar
• SHAHIDULLAH M, WILSON WS, MILLAR C: Effects of timolol, terbutaline and forskolin on TOP, aqueous humour formation and ciliary cyclic AMP levels in the bovine eye. Carr: Eye Res. (1995) 14:519–528.
   PubMed Web of Science ®Google Scholar
• FRISHMAN WH: Atenolol and timolol,two new systemic P-adrenoceptor antagonists. N Engl. J. Med. (1982) 306:1456–1462.
   PubMed Web of Science ®Google Scholar
• ZIMMERMAN TJ, KAUFMAN HE: Timolol. A P-adrenergic blocking agent for the treatment of glaucoma. Arch. Ophthalmol (1977) 95:601–604.
   PubMed Web of Science ®Google Scholar
• AMYOT M, BLONDEAU P: Timolol maleate. Pharmacology and review of the literature. Can. J. Ophthalmol (1979) 14:208–214.
   PubMed Web of Science ®Google Scholar
• ZIMMERMAN TJ, KAUFMAN HE: Timolol. Dose response and duration of action. Arch. Ophthalmol (1977) 95:605–607.
   PubMed Web of Science ®Google Scholar
• KIM JW, SMITH PH: Timolol-inducedbradycardia. Anesth. Analg. (1980) 59:301–301.
   PubMed Web of Science ®Google Scholar
• MCMAHON CD, SHAFFER RN, HOSKINS HD Jr, HETHERINGTON J Jr: Adverse effects experienced by patients taking timolol. Am.j Ophthalmol (1979) 88:736–738.
   PubMed Web of Science ®Google Scholar
• LARSSON L-I: Effect on intraocular pressure during 24 hours after repeated administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension. J. Glaucoma (2001) 10:109–114.
   PubMedGoogle Scholar
• BERGEA B, BODIN L, SVEDBERG B. Impact of intraocular pressure regulation on visual fields in open-angle glaucoma. Ophthalmology (1999) 106:997–1005.
   PubMed Web of Science ®Google Scholar
• ORZALESI N, ROSSETTI L, BOTTOLI A, FUMAGALLI E, FOGAGNOLO P: The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch. Ophthalmol (2003) 121:453–457.
   PubMed Web of Science ®Google Scholar
• CALISSENDORFF B, SJOQUIST B, HOGBERG G, GRUNGE-LOWERUD A: Bioavailability in the human eye of a fixed combination of latanoprost and timolol compared to monotherapy. °cal. Pharmacy]. Ther: (2002) 18:127–131.
   Google Scholar
• SJOQUIST B, STJERNSCHANTZ J: Ocular and systemic pharmacokinetics of latanoprost in humans. Surv. Ophthalmol. (2002) 47\(Suppl. 1):56–512.
   Google Scholar
• KORTE J-M, KAILA T, SAARI KM: Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefe's Arch. Clin. Exp. Ophthalmol (2002) 240:430–435.
   PubMedGoogle Scholar
• PATEL SS, SPENCER CM: Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging (1996) 9:363–378.
   PubMed Web of Science ®Google Scholar
• SCHUMAN JS: Short- and long-term safety of glaucoma drugs. Expert Opin. Drug Sal (2002) 1:181–194.
   PubMedGoogle Scholar
• VILLUMSEN J, ALM A: The effect of adding prostaglandin F2alpha-isopropylester to timolol in patients with open angle glaucoma. Arch. Ophthalmol (1990) 108:1102–1105.
   PubMedGoogle Scholar
• LEE PY, SHAO H, CAMRAS CB, PODOS SM: Additivity of prostaglandin F2alpha-1-isopropyl ester to timolol in glaucoma patients. Ophthalmology (1991) 98: 1079–1082.
   Google Scholar
• DIESTELHORST M, ALMEGARD B: Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma. Craefe's Arch. Clin. Exp. Ophthalmol (1998) 236:577-581.••An important clinical trial on the FClatanoprost/timolol with significantimpact on future treatment strategies.
   Google Scholar
• PFEIFFER N, for the EUROPEAN LATANOPROST FIXED COMBINATION STUDY GROUP: A comparison of the fixed combination of latanoprost and timolol with its individual components. Craefe's Arch. Clin. Exp. Ophthalmol (2002) 240:893-899.••An important clinical trial on FClatanoprost/timolol versus the UFC of the individual components, with specific focus on safety.
   Google Scholar
• HIGGINBOTHAM EJ, FELDMAN R, STILES M, DUBINER H, for the FIXED COMBINATION INVESTIGATIVE GROUP: Latanoprost and timolol combination therapy versus monotherapy. One-year randomized trial. Arch. Ophthalmol (2002) 120:915-922.••An important clinical trial on FClatanoprost/timolol versus monotherapy with latanoprost or timolol, with specific focus on safety.
   Google Scholar
• DIESTELHORST M, LARSSON L-I, for the EUROPEAN LATANOPROST FIXED COMBINATION STUDY GROUP: A 12-week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open-angle glaucoma and ocular hypertension. Br. fOphthalmol. (2004) 88:199–203.
   PubMed Web of Science ®Google Scholar
• ••An important comparative clinical trial ofFC latanoprost/timolol versus concomitant use of individual components.
   Google Scholar
• STEWART WC, STEWART JA, DAY D, SHARPE ED: Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily. Acta Ophthalmol Scand. (2003) 81:242–246.
   PubMedGoogle Scholar
• ••An important comparative clinical trial ofFC latanoprost/timolol versus. UFC brimonidine and latanoprost.
   Google Scholar
• GARCIA-SANCHEZ J, ROULAND J-F, SPIEGEL D et al.: A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six-month, evaluator-masked, multicenter study in Europe. Br. I. Ophthalmol Forthcoming.
   Google Scholar
• ••An important comparative clinical trial ofFC latanoprost/timolol versus UFC brimonidine and timolol.
   Google Scholar
• SHIN DH, FELDMAN RIVI, SHEU W-P, and MEMBERS OF THE FIXED COMBINATION LATANOPROST/TIMOLOL STUDY GROUP: Efficacy and safety of fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology (2004) 111:276–282.
   PubMed Web of Science ®Google Scholar
• ••An important comparative clinical trial ofFC latanoprost/timolol versus FC dorzolarnide/timolol.
   Google Scholar
• STEWART JA, STEWART WC, DAY DG, SHARPE ED, LEECH JN: Efficacy and safety of latanoprost/timolol maleate fixed combination versus brimonidine given twice daily and latanoprost given each evening. Invest. Ophthalmol Vis. Sri. (2003) (ARVO-Abstract 4364).
   Google Scholar
• ••An important comparative clinical trial ofFC latanoprost/timolol versus. UFC brimonidine and latanoprost.
   Google Scholar
• LESKE MC, HEIJL A, HUSSEIN M, BENGTSSON B, HYMAN L, KOMAROFF E, for THE EARLY MANIFEST GLAUCOMA TRIAL GROUP: Factors for glaucoma progression and the effect of treatment. The early manifest glaucoma trial. Arch. Ophthahnol (2003) 121:48–56.
   Google Scholar
• CART WRIGHT MT, ANDERSON DR. Correlation of asymmetric damage with asymmetric intraocular pressure in normal-tension glaucoma (low-tension glaucoma). Arch. Ophthalmol (1988) 106:898–900.
   PubMedGoogle Scholar
• LASS JH, ERIKSSON GL,OSTERLING L, SIMPSON CV, for THE LATANOPROST CORNEAL EFFECTS STUDY GROUP: Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol. A double-masked, randomized, one-year study. Ophthalmology (2001) 108:264–271.
   PubMed Web of Science ®Google Scholar
• DIALOG WEB [database online]: File 445:IMS R&D Focus© 2003 IMS Health & Affiliates. Accessed September 15, 2003.
   Google Scholar
• XALACOIVr (product monograph): Mississauga, Ontario, Canada; Pharmacia Canada, (September 26, 2002).
   Google Scholar
• http://www.pslgroup.com/dg/215472.htm Doctor's Guide website. Xalacom®(fixed combination 0.005% latanoprost and 0.5% 6m0109.
   Google Scholar